^
Association details:
| Biomarker: | EML4-NTRK3 rearrangement |
|---|---|
| Cancer: | Spindle Cell Sarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
Published date:
10/09/2023
Excerpt:
...we report the case of a patient affected by EML4-NTRK3 rearranged undifferentiated spindle cell bone sarcoma treated with larotrectinib...the patient is still on treatment with no evidence of disease after 14 months from larotrectinib rechallenge.
DOI:
https://doi.org/10.3389/fonc.2023.1252359
